CAMBRIDGE, Mass., Jan. 12, 2024 – Arena BioWorks announces its inauguration as a leading-edge biomedical research institute. With its mission firmly rooted in deciphering the mechanisms of human diseases and propelling technological innovations, Arena BioWorks is poised to transform these insights into lifesaving therapeutics through its internal biotech companies.
Co-Founders and Visionaries
The foundation of Arena BioWorks is underpinned by a distinguished group of co-founders. Stuart Schreiber, a renowned scientist from Harvard University and co-founder of the Broad Institute, joins forces with Steve Pagliuca, former Co-Chair of Bain Capital, and Tom Cahill of Newpath Partners, a life science venture capital firm. This trio brings a blend of scientific acumen and visionary leadership to the institute.
Core Scientific Team
The scientific endeavors at Arena BioWorks are spearheaded by leaders in their respective fields. Stuart Schreiber and Keith Joung lead the team, with other eminent scientists set to join. Their expertise in chemical biology and CRISPR gene editing is central to the institute’s innovative research trajectory.
Founding Investors
The institute’s initial phase has been made viable through the substantial backing of Steve Pagliuca, Michael Dell, Michael Chambers, Jim Breyer, and Elisabeth DeLuca. Their support establishes a foundational model for self-sustainability at Arena BioWorks.
Arena’s Novel Approach
Distinct in its operation, Arena BioWorks departs from conventional research models by utilizing a private funding approach. This strategy facilitates a swifter transition from insight discovery to practical application, free from the usual constraints of grant and venture capital dependencies. Arena BioWorks’ research encompasses a broad spectrum of diseases, harnessing a suite of advanced technologies including chemoproteomics, gene editing, and artificial intelligence.
Leadership and Impact
Under the stewardship of Stuart Schreiber, Steve Pagliuca, and Tom Cahill, Arena BioWorks is guided by an amalgamation of expertise in biotechnology, venture capitalism, and scientific innovation. The institute aspires to be a perpetual center of excellence, reinvesting its profits back into ongoing research and development. This innovative model sets a new standard in the biomedical research field.
https://www.nytimes.com/2024/01/12/business/arena-bioworks-scientists-harvard-mit.html
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
MeiraGTx’s AAV Gene Therapy Shows Promising Results for Parkinson’s
MeiraGTx has reported encouraging results from a midphase trial of its investigational gene therapy, AAV-GAD, for treating Parkinson’s disease. The company is now in discussions with regulators to advance the program to Phase III clinical trials.Significant...
[2024/10/11] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Ultragenyx Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study for Wilson Disease with AAV9 Gene Therapy
October 3, 2024 NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced promising results from the ongoing Phase 1/2/3 Cyprus2+ study evaluating UX701 gene therapy for Wilson disease. Early-stage data from Stage 1 of the trial revealed significant...
World-First CAR-T Therapy Using Donor Cells Sends Autoimmune Diseases into Remission
In a groundbreaking advancement, three individuals suffering from severe autoimmune diseases have achieved remission after receiving a revolutionary therapy using donor-derived immune cells. This pioneering treatment, which utilized bioengineered immune cells known as...
Related Services